| Drug Name |
Bortezomib |
| Drug ID |
BADD_D00284 |
| Description |
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083]
Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307] |
| Indications and Usage |
Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.[L14177] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XG01 |
| DrugBank ID |
DB00188
|
| KEGG ID |
D03150
|
| MeSH ID |
D000069286
|
| PubChem ID |
387447
|
| TTD Drug ID |
D0SH3I
|
| NDC Product Code |
62158-0011; 65129-1264; 0409-1703; 70710-1411; 51817-586; 68001-541; 14096-140; 0143-9098; 67184-0530; 71288-118; 72205-183; 63323-821; 12502-5268; 42385-716; 55111-922; 63323-721; 68001-534; 48957-0018; 10019-991; 70225-1102; 50742-484; 70511-161; 47848-031; 54893-0011; 66529-0006; 76055-0027; 82920-006; 0409-1704; 70771-1708; 72266-243; 72266-244; 54245-7004; 62207-972; 67184-0026; 60505-6050; 70511-162; 25021-244; 68001-540; 42973-140; 55150-337; 63020-049; 0409-1700; 70860-225; 62756-982; 68554-0051; 78848-009 |
| UNII |
69G8BD63PP
|
| Synonyms |
Bortezomib | LDP-341 | LDP 341 | LDP341 | PS 341 | 341, PS | PS-341 | PS341 | Velcade |
